Business · Companies · 1 hr ago
TDS Pharm seeks overseas patents for non-opioid pain patch
South Korean company TDS Pharm filed overseas patent applications for a non-opioid pain patch in the United States, Europe and Japan.
The patch is designed to deliver medicine through the skin and excludes opioid ingredients and skin penetration enhancers.
In January, the company registered a South Korean patent for a combined formula containing a non-steroidal anti-inflammatory drug, a local anesthetic and an antidepressant.
TDS Pharm says the patch aims to keep medicine levels steady and reduce skin side effects, while offering an alternative to opioid painkillers.
It is intended for pain ranging from muscle aches to chronic cancer, nerve-related and inflammatory pain.
The company plans to make and supply finished products itself from its plant in Osong, rather than transfer the product rights.
Patent approval and supply deals with global drug distributors are still ahead, so the company’s plans depend on securing those rights and agreements.
TDS Pharm has filed for patents in the United States, Europe and Japan for a non-opioid pain patch.
The formulation excludes opioid ingredients and skin penetration enhancers.
The company says its transdermal technology aims to maintain consistent drug levels and reduce skin side effects.
The patch is intended for pain ranging from muscle aches to cancer-related chronic, neuropathic and inflammatory pain.
TDS Pharm plans to pursue supply contracts for finished products rather than transfer the product rights.
- Who
- TDS Pharm, a company specializing in transdermal drug delivery systems.
- What
- It has filed overseas patents for a non-opioid pain patch formulation.
- When
- The company announced the filings on November 19, 2026.
- Where
- The patent applications cover the United States, Europe and Japan.
- Why
- It aims to secure global rights for the technology and pursue overseas supply opportunities as demand for non-opioid pain treatments grows.
This story does not have two clearly opposing sides.
TDS Pharm registered a domestic patent for a combination formulation of a non-steroidal anti-inflammatory drug, a local anesthetic and an antidepressant.
The company filed patent applications in the United States, Europe and Japan for its non-opioid transdermal formulation.
TDS Pharm announced the overseas patent filings.
- Patent markets
- United States, Europe and Japan
- Formulation
- Excludes opioid ingredients and skin penetration enhancers
- Domestic patent
- Registered in January 2026
- Production site
- Osong GMP plant
- Target uses
- Muscle aches, cancer-related chronic pain, neuropathic pain and inflammatory pain
What people are saying
After obtaining the patents, we plan to pursue supply contracts with global pharmaceutical distributors seeking next-generation combination patch formulations as existing patch patents expire.
We will make a leap forward as a high-value biotech company with foundational technology.